生物制药公司Ardelyx（纳斯达克股票代码：ARDX）在夜盘交易中股价大涨7.29%，主要受益于公司发布的2025年第二季度财报优于市场预期。
根据公司公布的财报，Ardelyx第二季度调整后每股亏损为0.08美元，明显好于分析师平均预期的0.13美元亏损。公司季度营收达到9766万美元，同比增长33.4%，同样超过了市场预期的8108万美元。这一亮眼的业绩表现引发了投资者的积极反应，推动股价在夜盘交易中大幅上涨。
值得注意的是，尽管Ardelyx在本季度表现出色，但公司今年以来的股价仍下跌了14.6%。然而，华尔街分析师对公司前景持乐观态度。目前，分析师对Ardelyx的平均评级为"买入"，12个月目标价中位数为10.00美元，较最新收盘价4.33美元有约56.7%的上涨空间。这表明分析师认为公司具有较大的增长潜力，可能会吸引更多投资者的关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.